Open AccessSerum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
Author(s) -
Khatib Mohamad Y.,
Allafi Solaiman M.,
Nashwan Abdulqadir J.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3642
Subject(s) - medicine , rituximab , pemphigus vulgaris , rash , myalgia , serum sickness , adverse effect , dermatology , immunology , antibody
Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patient with rituximab for pemphigus vulgaris.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom